

SAFETY DATA SHEET

SECTION 1 : IDENTIFICATION

Product Name: Micafungin Sodium for Injection, 100 mg/vial
Manufacturer Name: Gland Pharma Limited
Address: Survey No.: 143 - 148, 150 & 151, Near Gandimaisamma Cross Roads
 D.P. Pally, Quthubullapur Mandal - Ranga Reddy District
 Hyderabad, Andhra Pradesh 500 043
 India
General Phone Number: +91-40-30510999
General Fax Number: +91-40-30510810
Emergency Phone Number: +91-40-30510999
Distributor Name: Fresenius Kabi USA, LLC
Address: Three Corporate Drive
 Lake Zurich, Illinois 60047
General Phone Number: (847) 550-2300
Health Issues Information: (800) 551-7176
SDS Creation Date: January 15, 2020
SDS Revision Date: April 14, 2020

SECTION 2 : HAZARD(S) IDENTIFICATION

Signal Word: Not applicable.
Hazard Statements: Not applicable.
Precautionary Statements: Not applicable.

Emergency Overview: This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.

Route of Exposure: Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential Health Effects: Occupational exposure has not been fully investigated.

Eye: Contact with eyes may cause irritation.
Skin: May cause skin irritation.
Inhalation: May cause irritation of respiratory tract.
Ingestion: May cause irritation.

Signs/Symptoms: Potential adverse reactions from prescribed doses and overdoses are described in the package insert. Occupational exposure has not been fully investigated.

Aggravation of Pre-Existing Conditions: Individuals with hypernatremia or fluid retention. Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. Solutions that contain acetate ions should be used with great care in patients with metabolic or respiratory alkalosis and hepatic insufficiency.

SECTION 3 : COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS#	Ingredient Percent	EC Num.
Micafungin sodium	208538-73-2	100 mg/Vial by weight	
Lactose monohydrate	63-42-3	200 mg/Vial by weight	
Citric acid anhydrous	77-92-9	Quantity sufficient by weight	
Sodium hydroxide	1310-73-2	Quantity sufficient by weight	
Water for Injection	7732-18-5	Quantity Sufficient	

SECTION 4 : FIRST AID MEASURES

Eye Contact: Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of the eyes by separating the eyelids with fingers. Get immediate medical attention.

Skin Contact:	Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists.
Inhalation:	If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention.
Ingestion:	If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.
Other First Aid:	For Adverse Event Information, please call (800) 551-7176.

SECTION 5 : FIRE FIGHTING MEASURES

Flash Point:	Not established.
Flash Point Method:	Not established.
Auto Ignition Temperature:	Not established.
Lower Flammable/Explosive Limit:	Not established.
Upper Flammable/Explosive Limit:	Not established.
Fire Fighting Instructions:	Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible, contain fire run-off water.
Extinguishing Media:	Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires involving this material. Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Protective Equipment:	As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear.
Hazardous Combustion Byproducts:	Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of combustion.

SECTION 6 : ACCIDENTAL RELEASE MEASURES

Personal Precautions:	Avoid all contact with skin, eyes, or clothing. Avoid breathing (dust). Avoid generating dust Evacuate area and keep unnecessary and unprotected personnel from entering the spill area. Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as listed in Section 8.
Environmental Precautions:	Avoid runoff into storm sewers, ditches, and waterways.
Methods for containment:	Contain spills with an inert absorbent material such as soil, sand or oil dry.
Methods for cleanup:	Absorb spill with inert material (e.g., dry sand or earth), then place in a chemical waste container. After removal, flush spill area with soap and water to remove trace residue.

SECTION 7 : HANDLING and STORAGE

Handling:	When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions.
Storage:	Store at controlled room temperature 20 to 25°C (68 to 77°F).
Work Practices:	Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.
Hygiene Practices:	Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

Engineering Controls:	General ventilation is sufficient if this product is being used in a controlled medical setting (clinic, hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended exposure limits.
Eye/Face Protection:	Chemical splash goggles. Wear a face shield also when splash hazard exist.
Skin Protection Description:	Protective laboratory coat, apron, or disposable garment recommended.
Hand Protection Description:	Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data. Nitrile rubber or natural rubber gloves are recommended.
Respiratory Protection:	No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site (http://www.cdc.gov/niosh/npptl/topics/respirators/) for a list of respirator types and approved suppliers.
Other Protective:	Consult with local procedures for selection, training, inspection and maintenance of the personal protective equipment.

SECTION 9 : PHYSICAL and CHEMICAL PROPERTIES

Physical State:	Lyophilized cake/powder.
Color:	White
Boiling Point:	Not established.
Melting Point:	Not established.
Solubility:	Not established.
Vapor Density:	Not established.
Vapor Pressure:	Not established.
Percent Volatile:	Not established.
pH:	5.0 - 7.0
Molecular Weight:	No data available.
Flash Point:	Not established.
Flash Point Method:	Not established.
Auto Ignition Temperature:	Not established.

SECTION 10 : STABILITY and REACTIVITY

Chemical Stability:	Stable under normal temperatures and pressures.
Hazardous Polymerization:	Not reported.
Conditions to Avoid:	Direct sunlight. Extremely high or low temperatures. Ignition sources. Incompatible materials. Avoid creating or spreading dust.
Incompatible Materials:	Oxidizers
Special Decomposition Products:	Carbon oxides (CO, CO ₂). Nitrogen oxides. sulfur oxides. Sodium oxides.

SECTION 11 : TOXICOLOGICAL INFORMATION

Acute Toxicity:	Eye, skin, and respiratory irritation may occur.
Acute Effects:	Eye, skin, and respiratory irritation may occur.
Chronic Effects:	None known.
<u>Sodium hydroxide :</u>	
RTECS Number:	WB4900000

SECTION 12 : ECOLOGICAL INFORMATION

Ecotoxicity:	No ecotoxicity data was found for the product.
Environmental Stability:	No environmental information found for this product.

SECTION 13 : DISPOSAL CONSIDERATIONS

Waste Disposal:	Dispose of in accordance with Local, State, Federal and Provincial regulations.
-----------------	---

SECTION 14 : TRANSPORT INFORMATION

DOT Shipping Name:	Not Regulated.
DOT UN Number:	Not Regulated.

SECTION 15 : REGULATORY INFORMATION

EINECS Number:	810-840-7
EINECS Number:	200-559-2

SECTION 16 : ADDITIONAL INFORMATION

HMIS Ratings:

HMIS Health Hazard: 3*
HMIS Fire Hazard: 0
HMIS Reactivity: 0
HMIS Personal Protection: X

SDS Creation Date: January 15, 2020

SDS Revision Date: April 14, 2020

SDS Revision Notes: Updated HMIS Ratings.

Copyright© 1996-2018 Enviance. All Rights Reserved.